<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00625183</url>
  </required_header>
  <id_info>
    <org_study_id>I 113607</org_study_id>
    <secondary_id>RPCI-I-113607</secondary_id>
    <nct_id>NCT00625183</nct_id>
  </id_info>
  <brief_title>Capecitabine, Oxaliplatin, Selenomethionine, and Radiation Therapy in Treating Patients Undergoing Surgery For Newly Diagnosed Stage II or III Rectal Adenocarcinoma</brief_title>
  <official_title>A Phase II Study of Capecitabine, Oxaliplatin and Selenomethionine and Radiation Therapy in Patients With Stage II and III Rectal Adenocarcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Roswell Park Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Roswell Park Cancer Institute</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as capecitabine and oxaliplatin, work in&#xD;
      different ways to stop the growth of tumor cells, either by killing the cells or by stopping&#xD;
      them from dividing. Selenomethionine may slow the growth of tumor cells. Radiation therapy&#xD;
      uses high-energy x-rays to kill tumor cells. Giving combination chemotherapy together With&#xD;
      selenomethionine and radiation therapy may kill more tumor cells.&#xD;
&#xD;
      PURPOSE: This phase II trial is studying how well selenomethionine works when given together&#xD;
      with capecitabine, oxaliplatin, and radiation therapy in treating patients undergoing surgery&#xD;
      for newly diagnosed stage II or stage III rectal cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  To determine the complete pathological response rate of the combination of capecitabine,&#xD;
           oxaliplatin, selenomethionine, and radiotherapy in patients with stage II or III rectal&#xD;
           adenocarcinoma.&#xD;
&#xD;
        -  To determine the T-downstaging rate with this regimen in patients with stage II or III&#xD;
           rectal adenocarcinoma.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  To determine the safety of this regimen by assessing toxicity and dose intensity of the&#xD;
           various components of this regimen.&#xD;
&#xD;
        -  To determine the rate of local relapse.&#xD;
&#xD;
        -  To determine the rate of distant relapse.&#xD;
&#xD;
      OUTLINE: Patients receive neoadjuvant therapy comprising oral selenomethionine twice daily&#xD;
      for 1 week prior to radiotherapy and then once daily for 6 weeks. Patients also receive&#xD;
      oxaliplatin IV over 2 hours on days 1-7 and oral capecitabine twice daily on days 1-5 for 6&#xD;
      weeks and undergo radiotherapy 5 days a week for 6 weeks. Treatment continues in the absence&#xD;
      of disease progression or unacceptable toxicity.&#xD;
&#xD;
      Within 4-8 weeks after completion of neoadjuvant therapy, patients undergo curative-intent&#xD;
      surgery. Beginning 4-8 weeks after surgery, patients may receive up to 9 courses of standard&#xD;
      adjuvant combination chemotherapy (FOLFOX).&#xD;
&#xD;
      Blood samples are collected at baseline and weekly during treatment and analyzed by&#xD;
      absorption spectrophotometry for selenium measurement of drug concentration. Pharmacokinetic&#xD;
      studies are also performed.&#xD;
&#xD;
      After completion of study treatment, patients are followed for up to 5 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Withdrawn due to poor/low accrual&#xD;
  </why_stopped>
  <start_date>March 2008</start_date>
  <completion_date type="Actual">December 2009</completion_date>
  <primary_completion_date type="Actual">October 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Complete Pathological Response Rate</measure>
    <time_frame>After completion of capecitabine, oxaliplatin, selenomethionine, and radiation, and before surgery. Assessed endoscopically.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate of T-downstaging With Capecitabine, Oxaliplatin, Selenomethionine, and Radiotherapy</measure>
    <time_frame>After completion of capecitabine, oxaliplatin, selenomethionine, and radiation, and before surgery. Assessed endoscopically.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety and Tolerability as Assessed by NCI CTCAE Version 3.0</measure>
    <time_frame>Adverse events were queried for and collected every cycle for the duration of treatment.</time_frame>
    <description>Number of participants with any adverse event as assessed by NCI CTCAE version 3.0.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose Intensity</measure>
    <time_frame>During treatment with capecitabine, oxaliplatin, selenomethionine.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Local Relapse Rate</measure>
    <time_frame>For up to 5 years following surgery.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distant Relapse Rate</measure>
    <time_frame>For up to 5 years following surgery.</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">5</enrollment>
  <condition>Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>Capecitabine, Oxaliplatin, Selenomethionine, Radiation Therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oxaliplatin: 50 mg/m2 weekly x 5 Capecitabine 725 mg/m2BID on days of RT Selenomethionine: 4000mcg/m2 PO BID X 7 days prior to RT, then 4000mcg/m2 PO QD from first to last day of RT, including weekends</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>selenomethionine</intervention_name>
    <arm_group_label>Capecitabine, Oxaliplatin, Selenomethionine, Radiation Therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>capecitabine</intervention_name>
    <arm_group_label>Capecitabine, Oxaliplatin, Selenomethionine, Radiation Therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>oxaliplatin</intervention_name>
    <arm_group_label>Capecitabine, Oxaliplatin, Selenomethionine, Radiation Therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
    <arm_group_label>Capecitabine, Oxaliplatin, Selenomethionine, Radiation Therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>pharmacological study</intervention_name>
    <arm_group_label>Capecitabine, Oxaliplatin, Selenomethionine, Radiation Therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>adjuvant therapy</intervention_name>
    <arm_group_label>Capecitabine, Oxaliplatin, Selenomethionine, Radiation Therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>neoadjuvant therapy</intervention_name>
    <arm_group_label>Capecitabine, Oxaliplatin, Selenomethionine, Radiation Therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>therapeutic conventional surgery</intervention_name>
    <arm_group_label>Capecitabine, Oxaliplatin, Selenomethionine, Radiation Therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
    <arm_group_label>Capecitabine, Oxaliplatin, Selenomethionine, Radiation Therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed rectal adenocarcinoma that is involving the distal 12 cm of&#xD;
             the rectum (above the anal verge)&#xD;
&#xD;
               -  Staged within 8 weeks prior to initiation of study by endoscopic ultrasound OR&#xD;
                  MRI or CT scan if endorectal ultrasound is non-conclusive or non-tolerable&#xD;
&#xD;
               -  T3-T4 tumor or evidence of lymph node involvement defined by the presence of at&#xD;
                  least 1 enlarged peri-rectal lymph node&#xD;
&#xD;
          -  No evidence of distant or known metastases&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  ECOG performance status (PS) 0-1 OR Karnofsky PS 70-100%&#xD;
&#xD;
          -  Life expectancy &gt; 1 year&#xD;
&#xD;
          -  Leukocytes ≥ 3,000/µL&#xD;
&#xD;
          -  Absolute neutrophil count ≥ 1,500/µL&#xD;
&#xD;
          -  Platelet count ≥ 100,000/µL&#xD;
&#xD;
          -  Total bilirubin ≤ upper limit of normal (ULN)&#xD;
&#xD;
          -  AST/ALT ≤ 2.5 times ULN&#xD;
&#xD;
          -  Creatinine ≤ ULN OR creatinine clearance ≥ 60 mL/min&#xD;
&#xD;
          -  Able to receive oral medication&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No other concurrent or previous malignancies unless disease free for &gt; 5 years&#xD;
             (excluding nonmelanoma skin cancer)&#xD;
&#xD;
          -  No neuropathy ≥ grade 2&#xD;
&#xD;
          -  No history of allergic reaction attributed to compounds of similar chemical or&#xD;
             biologic composition to oxaliplatin, capecitabine, or selenomethionine&#xD;
&#xD;
          -  No uncontrolled intercurrent illness including, but not limited to, any of the&#xD;
             following:&#xD;
&#xD;
               -  Ongoing or active infection&#xD;
&#xD;
               -  Symptomatic congestive heart failure&#xD;
&#xD;
               -  Unstable angina pectoris&#xD;
&#xD;
               -  Cardiac arrhythmia&#xD;
&#xD;
               -  Psychiatric illness/social situations that would limit compliance with study&#xD;
                  requirements&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  No prior radiotherapy to the pelvis&#xD;
&#xD;
          -  No prior chemotherapy&#xD;
&#xD;
          -  No other concurrent investigational or anticancer agents or therapies&#xD;
&#xD;
          -  No concurrent vitamin B6 supplementation (except as part of a standard, multivitamin&#xD;
             supplement)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marwan Fakih, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Roswell Park Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Roswell Park Cancer Institute</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263-0001</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <study_first_submitted>February 26, 2008</study_first_submitted>
  <study_first_submitted_qc>February 26, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 28, 2008</study_first_posted>
  <results_first_submitted>September 19, 2014</results_first_submitted>
  <results_first_submitted_qc>September 19, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 26, 2014</results_first_posted>
  <last_update_submitted>October 13, 2017</last_update_submitted>
  <last_update_submitted_qc>October 13, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 17, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>adenocarcinoma of the rectum</keyword>
  <keyword>stage II rectal cancer</keyword>
  <keyword>stage III rectal cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Selenium</mesh_term>
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Capecitabine, Oxaliplatin, Selenomethionine and Radiation Ther</title>
          <description>Oxaliplatin: 50 mg/m2 weekly x 5 Capecitabine 725 mg/m2BID on days of RT Selenomethionine: 4000mcg/m2 PO BID X 7 days prior to RT, then 4000mcg/m2 PO QD from first to last day of RT, including weekends</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Disease Progression</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All treated and eligible patients</population>
      <group_list>
        <group group_id="B1">
          <title>Capecitabine, Oxaliplatin, Selenomethionine and Radiation Ther</title>
          <description>Oxaliplatin: 50 mg/m2 weekly x 5 Capecitabine 725 mg/m2BID on days of RT Selenomethionine: 4000mcg/m2 PO BID X 7 days prior to RT, then 4000mcg/m2 PO QD from first to last day of RT, including weekends</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="5"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56.48" spread="6.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Complete Pathological Response Rate</title>
        <time_frame>After completion of capecitabine, oxaliplatin, selenomethionine, and radiation, and before surgery. Assessed endoscopically.</time_frame>
        <population>Due to the study's early termination, as a result of low accrual, target accrual was not reached and no data was not collected for this assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Capecitabine, Oxaliplatin, Selenomethionine, Radiation Therapy</title>
            <description>Oxaliplatin: 50 mg/m2 weekly x 5 Capecitabine 725 mg/m2BID on days of RT Selenomethionine: 4000mcg/m2 PO BID X 7 days prior to RT, then 4000mcg/m2 PO QD from first to last day of RT, including weekends</description>
          </group>
        </group_list>
        <measure>
          <title>Complete Pathological Response Rate</title>
          <population>Due to the study's early termination, as a result of low accrual, target accrual was not reached and no data was not collected for this assessment.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Rate of T-downstaging With Capecitabine, Oxaliplatin, Selenomethionine, and Radiotherapy</title>
        <time_frame>After completion of capecitabine, oxaliplatin, selenomethionine, and radiation, and before surgery. Assessed endoscopically.</time_frame>
        <population>Due to the study's early termination, as a result of low accrual, target accrual was not reached and no data was collected for this assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Capecitabine, Oxaliplatin, Selenomethionine, Radiation Therapy</title>
            <description>Oxaliplatin: 50 mg/m2 weekly x 5 Capecitabine 725 mg/m2BID on days of RT Selenomethionine: 4000mcg/m2 PO BID X 7 days prior to RT, then 4000mcg/m2 PO QD from first to last day of RT, including weekends</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of T-downstaging With Capecitabine, Oxaliplatin, Selenomethionine, and Radiotherapy</title>
          <population>Due to the study's early termination, as a result of low accrual, target accrual was not reached and no data was collected for this assessment.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Safety and Tolerability as Assessed by NCI CTCAE Version 3.0</title>
        <description>Number of participants with any adverse event as assessed by NCI CTCAE version 3.0.</description>
        <time_frame>Adverse events were queried for and collected every cycle for the duration of treatment.</time_frame>
        <population>All treated and eligible patients</population>
        <group_list>
          <group group_id="O1">
            <title>Capecitabine, Oxaliplatin, Selenomethionine, Radiation Therapy</title>
            <description>Oxaliplatin: 50 mg/m2 weekly x 5 Capecitabine 725 mg/m2BID on days of RT Selenomethionine: 4000mcg/m2 PO BID X 7 days prior to RT, then 4000mcg/m2 PO QD from first to last day of RT, including weekends</description>
          </group>
        </group_list>
        <measure>
          <title>Safety and Tolerability as Assessed by NCI CTCAE Version 3.0</title>
          <description>Number of participants with any adverse event as assessed by NCI CTCAE version 3.0.</description>
          <population>All treated and eligible patients</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Dose Intensity</title>
        <time_frame>During treatment with capecitabine, oxaliplatin, selenomethionine.</time_frame>
        <population>Due to the study's early termination, as a result of low accrual, target accrual was not reached and no data was collected for this assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Capecitabine, Oxaliplatin, Selenomethionine,Radiation Therapy</title>
            <description>Oxaliplatin: 50 mg/m2 weekly x 5 Capecitabine 725 mg/m2BID on days of RT Selenomethionine: 4000mcg/m2 PO BID X 7 days prior to RT, then 4000mcg/m2 PO QD from first to last day of RT, including weekends</description>
          </group>
        </group_list>
        <measure>
          <title>Dose Intensity</title>
          <population>Due to the study's early termination, as a result of low accrual, target accrual was not reached and no data was collected for this assessment.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Local Relapse Rate</title>
        <time_frame>For up to 5 years following surgery.</time_frame>
        <population>Due to the study's early termination, as a result of low accrual, target accrual was not reached and no data was collected for this assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Capecitabine, Oxaliplatin, Selenomethionine and Radiation Ther</title>
            <description>Oxaliplatin: 50 mg/m2 weekly x 5 Capecitabine 725 mg/m2BID on days of RT Selenomethionine: 4000mcg/m2 PO BID X 7 days prior to RT, then 4000mcg/m2 PO QD from first to last day of RT, including weekends</description>
          </group>
        </group_list>
        <measure>
          <title>Local Relapse Rate</title>
          <population>Due to the study's early termination, as a result of low accrual, target accrual was not reached and no data was collected for this assessment.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Distant Relapse Rate</title>
        <time_frame>For up to 5 years following surgery.</time_frame>
        <population>Due to the study's early termination, as a result of low accrual, target accrual was not reached and no data was not collected for this assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Capecitabine, Oxaliplatin, Selenomethionine,Radiation Therapy</title>
            <description>Oxaliplatin: 50 mg/m2 weekly x 5 Capecitabine 725 mg/m2BID on days of RT Selenomethionine: 4000mcg/m2 PO BID X 7 days prior to RT, then 4000mcg/m2 PO QD from first to last day of RT, including weekends</description>
          </group>
        </group_list>
        <measure>
          <title>Distant Relapse Rate</title>
          <population>Due to the study's early termination, as a result of low accrual, target accrual was not reached and no data was not collected for this assessment.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Capecitabine, Oxaliplatin, Selenomethionine and Radiation Ther</title>
          <description>Oxaliplatin: 50 mg/m2 weekly x 5 Capecitabine 725 mg/m2BID on days of RT Selenomethionine: 4000mcg/m2 PO BID X 7 days prior to RT, then 4000mcg/m2 PO QD from first to last day of RT, including weekends</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abscess intestinal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="2" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Lymphopenia</sub_title>
                <counts group_id="E1" events="15" subjects_affected="5" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="7" subjects_affected="3" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Proctalgia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Radiation skin injury</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Haemoglobin decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Hypoalbuminaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Hypomagnesaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" events="7" subjects_affected="4" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Peripheral sensory neuropathy</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Bladder spasm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Micturition urgency</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Urinary incontinence</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Exfoliative rash</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Photosensitivity reaction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Skin odour abnormal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Due to the study's early termination, as a result of low accrual, target accrual was not reached and no statistical inference of the primary and secondary aims were carried forth.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Senior Administrator, Compliance - Clinical Research Services</name_or_title>
      <organization>Roswell Park Cancer Institute</organization>
      <phone>716-845-2300</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

